MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will participate in the "Gene Therapy Ascending? Today's Advancements Over Past Hurdles" panel at the 13thBIO Investor Forum on Wednesday, October 8, 2014 at 10:30 am PDT in San Francisco, CA.
About Avalanche Biotechnologies, Inc.
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet AMD. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information please visit www.avalanchebiotech.com.
CONTACT: Investor Contact:
Chris ErdmanMacDougall Biomedical Communications
(781) 235-3060
cerdman@macbiocom.com
Media Contact:
Kathy Vincent
(310) 403-8951
kathy@kathyvincent.com
Avalanche Biotechnologies, Inc.